Home > Publications Database > Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. > print

001     136371
005     20240321220045.0
024 7 _ |a 10.1016/j.ejca.2011.06.026
|2 doi
024 7 _ |a pmid:21745734
|2 pmid
024 7 _ |a 0014-2964
|2 ISSN
024 7 _ |a 0959-8049
|2 ISSN
024 7 _ |a 1879-0852
|2 ISSN
024 7 _ |a 1879-2995
|2 ISSN
037 _ _ |a DZNE-2020-02693
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Koppelmans, Vincent
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy.
260 _ _ |a Amsterdam [u.a.]
|c 2011
|b Elsevier
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2011-11-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710772864_18974
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Incidental brain findings defined as previously undetected abnormalities of potential clinical relevance that are unexpectedly discovered at brain imaging and are unrelated to the purpose of the examination are common in the general population. Because it is unclear whether the prevalence of incidental findings in breast cancer patients treated with chemotherapy is different to that in the general population, we compared the prevalence in breast cancer survivors treated with chemotherapy to that in a population-based sample of women without a history of any cancer.Structural brain MRI (1.5T) was performed in 191 female CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) chemotherapy-exposed breast cancer survivors. A reference group of 1590 women without a history of cancer was sampled from a population-based cohort study. All participants were aged 50 to 80 years. Five trained reviewers recorded the brain abnormalities. Two experienced neuro-radiologists reviewed the incidental findings.The cancer survivors had completed chemotherapy on average 21 years before. Of the 191 subjects, 2.6% had an aneurysm and 3.7% had a meningioma. The prevalence of meningiomas and aneurysms was not different between the groups. The prevalence of pituitary macro adenomas in the breast cancer survivors (1.6%) was higher than that in the reference group (0.1%) (OR=23.7; 95% CI 2.3-245.8).Contrary to commonly held opinions, we did not observe an increased prevalence of meningiomas in cancer survivors. Breast cancer survivors previously treated with chemotherapy are more likely to develop pituitary adenomas than persons without a history of cancer and chemotherapy treatment.
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 0
542 _ _ |i 2011-11-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 7 |a Cyclophosphamide
|0 8N3DW7272P
|2 NLM Chemicals
650 _ 7 |a Fluorouracil
|0 U3P01618RT
|2 NLM Chemicals
650 _ 7 |a Methotrexate
|0 YL5FZ2Y5U1
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Antineoplastic Agents: therapeutic use
|2 MeSH
650 _ 2 |a Antineoplastic Combined Chemotherapy Protocols: administration & dosage
|2 MeSH
650 _ 2 |a Breast Neoplasms: complications
|2 MeSH
650 _ 2 |a Breast Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Chemotherapy, Adjuvant
|2 MeSH
650 _ 2 |a Cyclophosphamide: administration & dosage
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Fluorouracil: administration & dosage
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Incidence
|2 MeSH
650 _ 2 |a Incidental Findings
|2 MeSH
650 _ 2 |a Intracranial Aneurysm: diagnosis
|2 MeSH
650 _ 2 |a Intracranial Aneurysm: epidemiology
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Meningioma: diagnosis
|2 MeSH
650 _ 2 |a Meningioma: epidemiology
|2 MeSH
650 _ 2 |a Methotrexate: administration & dosage
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neoplasms, Second Primary: diagnosis
|2 MeSH
650 _ 2 |a Neoplasms, Second Primary: epidemiology
|2 MeSH
650 _ 2 |a Pituitary Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Pituitary Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Survivors
|2 MeSH
700 1 _ |a Schagen, Sanne B
|0 P:(DE-HGF)0
|b 1
|e Corresponding author
700 1 _ |a Poels, Mariëlle M F
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Boogerd, Willem
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Seynaeve, Caroline
|0 P:(DE-HGF)0
|b 4
700 1 _ |a van der Lugt, Aad
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Breteler, Monique M B
|0 P:(DE-2719)2810403
|b 6
|e Last author
773 1 8 |a 10.1016/j.ejca.2011.06.026
|b : Elsevier BV, 2011-11-01
|n 17
|p 2531-2536
|3 journal-article
|2 Crossref
|t European Journal of Cancer
|v 47
|y 2011
|x 0959-8049
773 _ _ |a 10.1016/j.ejca.2011.06.026
|g Vol. 47, no. 17, p. 2531 - 2536
|0 PERI:(DE-600)1468190-0
|n 17
|q 47:17<2531 - 2536
|p 2531-2536
|t European journal of cancer
|v 47
|y 2011
|x 0959-8049
856 4 _ |u https://pub.dzne.de/record/136371/files/DZNE-2020-02693_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/136371/files/DZNE-2020-02693_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:136371
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810403
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 0
914 1 _ |y 2011
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J CANCER : 2017
920 1 _ |0 I:(DE-2719)1012001
|k AG Breteler
|l Population Health Sciences
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1012001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21